OPINION

Why Gathering Health Economic Data for Cancer Drugs is Now Essential

Why Gathering Health Economic Data for Cancer Drugs is Now Essential

Health economic and outcomes research datasets have rarely been integral to product development and communication plans.

4 Industry Execs Examine the State of Physician-Rep Access

4 Industry Execs Examine the State of Physician-Rep Access

Recent polls paint a mixed picture of physicians' willingness to see pharma sales reps. What gives? Are no-see docs up or down, and what's behind the dissonant findings?

Making the Case for the Value of Co-pay Cards

Making the Case for the Value of Co-pay Cards

Now that payers are locking in discounts at launch from drugmakers, where do co-pay cards fit in the marketing mix?

Speeding up FDA Approvals Calls for Pause

Speeding up FDA Approvals Calls for Pause

The idea that 30 days is enough time for the FDA to evaluate anything is, of course, quite silly. But Sen. Cruz takes it one step further.

Natrel's Oppici Wades into Unbranded Cancer Ads

Natrel's Oppici Wades into Unbranded Cancer Ads

Here are some compelling campaigns that invoke a visceral response—you laugh, cry, even cringe—followed by a more thoughtful and inspired reaction to learn more.

A Competitive Market is Good for US Patients

A Competitive Market is Good for US Patients

We look forward to collaborating with stakeholders across the healthcare system—including PBMs—to extend success to disease states beyond hepatitis C, writes PhRMA CEO Stephen Ubl.

Is This the End of Agency Diversification?

Is This the End of Agency Diversification?

DTC and OTC/wellness can borrow from mainstream consumer shops. Professional marketing may pose a tougher sell.

Marketers Rely on Email and Social Media, Rather than Face Time

Marketers Rely on Email and Social Media, Rather than Face Time

Curating personal relationships is one of the most valuable functions medical marketers can provide. The best way is through face-to-face interaction.

Hey Pharma—Chin Up, Fella!

Hey Pharma—Chin Up, Fella!

The traditional line of attack is genuine and requires little in the way of spin—yet still, every time a Turing rears its head, it gets blown back in small and indigestible pieces.

4 Ways to Create a Sustainable Pricing Model

4 Ways to Create a Sustainable Pricing Model

The formula's pretty simple: Be sure you can defend your drug's value proposition, without blushing, says BioPharma Alliance's Mike Luby.

Email Newsletters